Trenbolone Enanthate

Description

Trenbolone Enanthate (Tren E) is the long-acting heptanoate ester of Trenbolone. Structurally Trenbolone is a 19-nortestosterone derivative with two additional double bonds that prevent aromatization and 5α-reduction. The enanthic acid ester variant has the same pharmacology as the acetate but substantially slower release kinetics.

Per study reports the elimination half-life of Tren E is about 7-10 days. Typical research protocols therefore manage with two weekly injections for stable plasma levels. Compared to Tren A this means substantially less injection-site stress but slower cycle adjustments mid-protocol.

Trenbolone binds with high affinity to the androgen receptor and doesn’t aromatize. As with all Tren esters, progestagenic activity exists that can lead to prolactin-mediated effects. The typical Tren effects (night sweats, sleep disturbances, aggression, unfavorable lipid profile, prolactin elevation) are present under Tren E but the slower flood-in may feel subjectively less intense than Tren A.

In recreational research practice Tren E is often used in medium-long cycles (8-12 weeks), while Tren A is typically used in shorter pre-contest setups. Both esters are pharmacologically equivalent - the difference lies only in injection frequency.

Trenbolone is on the WADA banned list.

You can order Trenbolone Enanthate as an oily injection solution in 10-pack at 200mg/ml.

This information is for research and educational purposes only. No medical recommendations.

Risks & Safety

Trenbolone Enanthate shares the full risk profile of all Tren esters - the slower flood-in may feel subjectively less intense than Tren A, but the documented effects are identical.

Documented in studies and the application literature:

• Progestagenic and prolactinergic action: Trenbolone acts progestagenically and drives prolactin levels up. Prolactin-mediated effects are documented. Trenbolone does not aromatize.
• Suppression of endogenous production: Trenbolone strongly suppresses endogenous testosterone production. Testicular atrophy and reduced fertility are documented, a separate test base is mandatory in research practice.
• Tren-typical effects: user reports describe night sweats, sleep disturbances and aggression. If side effects occur, clearance takes longer than with Tren A due to the longer half-life.
• Cardiovascular and liver: the literature describes an unfavorable lipid profile, cardiac effects are documented in preclinical models. Hepatotoxicity is lower than under oral 17-alpha-methyl steroids but not negligible.

Baseline bloodwork before, during and after a research protocol is strongly advised. This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.

Studies

• 17β-Hydroxyestra-4,9,11-trien-3-one (trenbolone) exhibits tissue selective anabolic activity: effects on muscle, bone, adiposity, hemoglobin, and prostate - American Journal of Physiology-Endocrinology and Metabolism 2011, Yarrow et al: key study using Trenbolone Enanthate in castrated rats. Shows anabolic action at muscle without aromatization and without pronounced prostate stimulation.
• Characterisation of the affinity of different anabolics and synthetic hormones to the human androgen receptor, human sex hormone binding globulin and to the bovine progestin receptor - APMIS 2000, Bauer et al: measures the receptor binding profiles of 17β-trenbolone at AR, SHBG and progestin receptor, explaining the combined androgenic plus progestagenic profile of all Tren esters.
• Trenbolone Improves Cardiometabolic Risk Factors and Myocardial Tolerance to Ischemia-Reperfusion in Male Rats With Testosterone-Deficient Metabolic Syndrome - Endocrinology 2016, Donner et al: documents trenbolone effects on body fat, lipid profile and cardiac ischemia-reperfusion tolerance in a preclinical model.
• Improvements in body composition, cardiometabolic risk factors and insulin sensitivity with trenbolone in normogonadic rats - Steroids 2015, Donner et al: companion study in normogonadic rats showing improvements in insulin sensitivity and body composition over 6 weeks of trenbolone treatment.
• ‘My mind pretty much went to mush’: A qualitative exploration of trenbolone in the performance and image enhancing drug community - Drug and Alcohol Review 2023, Piatkowski et al: qualitative interview study on psychological side effects, aggression and sleep disturbances reported under trenbolone use.